Viatris Q1 revenue beats analyst estimates on China strength

Viatris

07/05/2026 12:07

Overview

US healthcare firm's Q1 revenue grew 8% yr/yr, beating analyst expectations

Adjusted EPS for Q1 rose 18% and beat analyst expectations

Growth driven by Greater China strength and new product launches

Outlook

Viatris sees 2026 total revenues between $14.45 bln and $14.95 bln

Company expects 2026 adjusted EPS between $2.33 and $2.47

Viatris continues to expect $450 mln to $550 mln in new product revenues in 2026

Result Drivers

GREATER CHINA GROWTH - Co said revenue growth was primarily driven by strong performance in Greater China

NEW PRODUCT LAUNCHES - Co said new product launches contributed to generics net sales and overall revenue

BRANDS SALES MOMENTUM - Co said brands net sales reflected accelerated growth in Greater China and continued strength in Emerging Markets

Company press release: ID:nPn6vwFJfa

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 Revenue
Beat
$3.52 bln
$3.36 bln (7 Analysts)
Q1 Adjusted EPS
Beat
$0.59
$0.50 (8 Analysts)
Q1 EPS
$0.15


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)